Cardiovascular risk assessment and lipid modification

changing lipid-lowering treatment who had a full lipid profile and their liver transaminases measured at 2 to 3 months. Numerator – the number in the denominator who had a full lipid profile and their liver transaminases measured at 2 to 3 months. Denominator – the number of adults starting or changing lipid-lowering treatment. Data source: Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example from electronic patient records. What the quality statement means for different audiences Service providers (such as primary care services or secondary care services) ensure that adults on lipid-lowering treatment have a full lipid profile and their liver transaminases measured 2 to 3 months after starting or changing treatment. Healthcare professionals (such as GPs, doctors, nurses and pharmacists) measure a full lipid profile and liver transaminases 2 to 3 months after adults start or change lipid- lowering treatment. Commissioners ensure that adults on lipid-lowering treatment have a full lipid profile and liver transaminases measured 2 to 3 months after starting or changing treatment. Adults taking medicine to reduce their chance of a heart attack or stroke have a blood test 2 to 3 months after starting or changing medicine to
